PeptideGlobal

Weight loss drugs in India reach two lakh households as PwC says use doubles each year

PwC estimates that about two lakh Indian households, mostly in the biggest metros, use GLP-1 drugs such as Ozempic and Mounjaro, spending Rs 8,000 to Rs 16,000 a month. The firm says the number doubles every year but did not publish its method.

Illustration for the story: Weight loss drugs in India reach two lakh households as PwC says use doubles each year

Illustration by Peptide Global, not a picture of the place in the story.

The short of itPwC estimates that about two lakh Indian households use GLP-1 drugs such as Ozempic and Mounjaro, mostly in the top metros, and says the number doubles every year.

Weight loss drugs in India are now used in about two lakh households, or roughly 200,000, according to an estimate the consultancy PwC gave reporters in Mumbai on 17 November. The figure covers GLP-1 medicines such as Ozempic and Mounjaro taken for diabetes or obesity. PwC said the number of user households doubles every year, which makes the market hard to size. It did not publish the method behind the estimate, so the number is best read as an informed industry view rather than a measured count.

What PwC told reporters in Mumbai

The estimate came from Ravi Kapoor, the partner who leads PwC's retail and consumer practice in India, speaking at the launch of a consumer survey, according to a Press Trust of India report carried by Mathrubhumi English. "2 lakh households are using GLP-1 drugs. Many of them are concentrated in the top five or six metros," Kapoor said. He explained that PwC counts homes rather than people because a husband and wife are often both taking the drugs, so the number of individual users is probably higher than the headline figure. Kapoor did not name the cities in that top tier or say how the count was built, whether from pharmacy sales, prescription audits or answers to a survey.

Kapoor also gave a spending range. Each household on these medicines spends between Rs 8,000 and Rs 16,000 a month, he said, and the drugs are sold only on prescription. He put the number of brands available in the country at about 20. That count reflects how crowded the field has become since Novo Nordisk's main semaglutide patent in India expired in March and domestic companies brought out their own versions. The spending range is wide because brands, strengths and pack sizes differ, and because a home with two users pays roughly twice as much. PwC did not say whether the figure includes doctor visits, blood tests or the other costs that come with treatment.

Why the doubling claim matters

Kapoor's boldest claim is the pace of growth. If the number of households really doubles each year, the two lakh figure would be out of date within months, which is one reason he called the overall market size very difficult to estimate. Sales data published elsewhere point the same way. Lilly's tirzepatide brand Mounjaro has climbed the Indian sales rankings, and this site reported earlier this month that Mounjaro India sales had overtaken the antibiotic Augmentin by value as generic semaglutide volumes jumped. Those figures measure money and packs sold, while the PwC number counts homes, so the two series cannot be compared directly, even if both describe the same quick rise.

If the number of households really doubles each year, the two lakh figure would be out of date within months, which is one reason he called the overall market size very difficult to estimate.

Two lakh households is still a small share of a country of well over a billion people with a heavy diabetes burden. Kapoor said the potential market is huge because diabetes and lifestyle related heart disease are so common, but PwC gave no forecast or time frame, and none is added here. The concentration in the largest metros fits what is known about cost and access. A monthly bill of several thousand rupees is beyond most families, and specialist prescribers cluster in big cities. Growth of weight loss drugs in India beyond the metros will depend on cheaper generics, wider prescribing by general doctors and any move by insurers or employers to pay for treatment.

The PwC survey behind the launch

The household estimate was a side remark. The main item was a PwC survey of 1,005 respondents in India, carried out in January and February. It found that 97 percent want to make long term well being a priority, while 67 percent named stress, fatigue or low energy as obstacles to a healthy daily routine. Kapoor said those barriers can include traffic, nuclear families and the demands of raising children. The reported findings did not cover GLP-1 medicines, so the two numbers come from different exercises: one a survey with a stated sample and fieldwork dates, the other an estimate whose method was not shared with reporters or published alongside the survey report.

ItemDetail
SourcePwC, remarks by Ravi Kapoor in Mumbai
Date17 November 2026
Households using GLP-1 drugsAbout two lakh, roughly 200,000
WhereMostly the top five or six metros
GrowthNumber of households doubling every year, PwC says
Monthly household spendRs 8,000 to Rs 16,000
Brands on the marketAbout 20
Consumer survey1,005 respondents, January and February
Method for household estimateNot disclosed

Indian respondents were also more worried than the global average about microplastics, protein intake, fibre content and calories, according to the survey. That pattern is relevant to anyone following weight loss drugs in India, because medicines that curb appetite reduce how much people eat and raise questions about protein and nutrient intake during treatment. Consumers who already track protein and fibre may be more open to diet advice from their doctor while on these drugs. The PTI report said the findings came out at a time of heightened public attention to food safety in the country. PwC did not link the two strands of its presentation, and the survey summary did not say how many respondents take any medicine for weight.

What to watch next

The first open question is method. A published breakdown of how PwC reached two lakh households, and whether it rests on pharmacy data or on survey answers, would let other analysts test the figure. The second is price. With about 20 brands competing and more generic semaglutide arriving, monthly costs may fall for some patients, which could widen use beyond the metros. The third is oversight. India's drug regulator issued an alert this autumn that flagged six Mounjaro KwikPen batches, and a fast growing market with many brands raises the stakes for checks on product quality and on prescribing. None of these questions was answered by the PwC remarks in Mumbai.

For readers outside India, the estimate gives a rough size for one of the largest emerging markets for these medicines, but comparisons need care. A Korean survey on GLP 1 use earlier this month counted individual adults who used or were prescribed an obesity drug, and it rested on a stated sample. The PwC number for weight loss drugs in India counts homes and has no published method. Together they show demand rising in two very different Asian markets, yet neither is a measured national rate of use. A prescription audit or a government survey would be the stronger evidence, and neither has been released for India so far.

Conclusion

PwC's estimate puts weight loss drugs in India in about two lakh households, mostly in the biggest cities, with spending of Rs 8,000 to Rs 16,000 a month and a user base the firm says doubles each year. It is an informed estimate without a published method. The useful next signals are a method note from PwC, prescription and sales audits that track generic semaglutide and Mounjaro, and any sign of insurers or employers paying for treatment.

Why it matters in India

India opened to generic semaglutide in March and now has about 20 brands. A first size estimate shows use is still concentrated in big cities among households that can pay several thousand rupees a month, so price and prescribing will decide how far the drugs spread.

What to watch

Whether PwC publishes the method behind the estimate, prescription audits for generic semaglutide and Mounjaro, price moves as more generics arrive, and any insurer or employer coverage.

Sources

  1. Mathrubhumi English (PTI): PwC estimates two lakh Indian households using GLP-1 drugs
  2. Business Standard: Indian drugmakers take generic semaglutide battle to overseas markets

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.